CClinicalTrials.gg
Not yet recruitingNCT06179394Updated Dec 21, 2023

Evaluation of Cognitive Dysfunction and Psychiatric Comorbidities

An observational study in Wilson Disease, sponsored by Assiut University. Not yet recruiting. Open to participants aged 8 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
40
Ages
8 Years to 70 Years
Sex
All
01

Study summary

Primary objective

  • Collection of patients with wilson disease either presented with neurological or hepatic symptoms
  • Assessment of psychiatric and cognitive disorders in both groups by using specific scales Secondary objective
  • correlation of MRI brain findings with cognitive \& psychiatric symptoms found in the patients ,if possible.
Read the detailed description

Wilson's disease is an autosomal recessive disorder of copper metabolism caused by ATP7B mutations. Originally described as hepatolenticular degeneration, it classically presents with the combination of liver disease and a movement disorder during adolescence or early adulthood, albeit with a highly variable phenotype. Up to 60% of patients have neurological or psychiatric symptoms at onset, and are referred to as having neurological presentations (1). Chelating agents are used to 'de-copper' patients but neurological outcomes are unpredictable; symptoms usually improve however, a minority have persistent or progressive neurological disability (2, 3).

It is clinically relevant that the severity of neurologic symptoms commonly fluctuates, sometimes during the same day. Symptoms may be exacerbated by stress, concurrent illnesses, or medications (4). WD has been associated with multiple cognitive, emotional, or psychiatric disorders, which may occur at any stage of disease (5 ). The first psychiatric manifestation of WD could occur in childhood and appear as a decline in school performance, inappropriate behavior or impulsiveness(6). It is common to observe classic psychiatric syndromes in later early adulthood, including behavioral and personality changes, anxiety, depression, manic and hypomanic syndrome, cognitive deficits (7-10). personality and behavioral disorder due to brain disease, damage and dysfunction' (11).The BG are a structure capable of generating diverse psychiatric syndromes under dysfunctional conditions. Cognitive impairment in WD patients with neuropsychiatric presentation is well described (12) and probably related to the cerebral lesions detected by MRI (13). WD patients will firstly experience prospective memory related to the planning or goal-making of daily activities (14), which is associated with gray matter loss in the basal ganglia and structural changes in frontal and occipital whiter matter (15).

02

Conditions studied

03

In context

Hepatolenticular Degeneration

78 studies on the registry are indexed under Hepatolenticular Degeneration; 30 are open to participants now.

This study's planned enrollment of 40 is below the median of 69 across 34 observational studies indexed under Hepatolenticular Degeneration.

Browse Hepatolenticular Degeneration studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

all pt fulfilling inclusion criteria will including in my study except that we exculded .

Inclusion criteria

  • age 8-70, both sexes, diagnosed as Wilson disease.

Exclusion criteria

Exclusion Criteria:

    • Patients with neurological symptoms due to neurological disease other than Wilson disease such as patients with cerebrovascular stroke or Parkinson disease, ......

      • Patients with hepatic encephalopathy or severe neurological impairments (disabling dysarthria, tremor or dystonia) or severe psychiatric disorders incompatible with neuropsychological examination
      • Patients with liver transplant
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. correlation

    • correlation of MRI brain findings with cognitive \& psychiatric symptoms found in the patients

    Time frame: base line

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06179394
Lead sponsor
Assiut University
Responsible party
Mustafa Ahmed Sedky Abdallah (doctor, Assiut University) — Principal investigator
First posted
Dec 21, 2023
Start date
Dec 15, 2023 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Dec 21, 2023

Study contacts

Mustafa A Sedky Abd-ALLAH, resident
Contact
sedky9752@gmail.com
01093194172
Anwar M Ali, prof
Contact
anwarmoha2006@aun.edu.eg
01030361010

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion